C$5.78 0.3 5.7%
Last Trade - 10/08/20
| Market Cap | £152.8m |
| Enterprise Value | £129.6m |
| Revenue | £n/a |
| Position in Universe | 462nd / 2675 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Mar | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.10 | ||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2020
|
31st Dec 2021
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Medicenna Therapeutics Corp, formerly A2 Acquisition Corp, is a Canada-based clinical stage immuno-oncology company. The Company is engaged in developing engineered versions of Interleukin (IL)-2, IL4 and IL13 cytokines called Superkines and Empowered Cytokines (ECs). The Company focuses on commercialization EC and Superkines for the treatment of cancer. The Company's IL4 EC is a drug that targets the Bulk Tumor, Cancer Stem Cells and Immunosuppressive Cells of the Tumor Micro-environment. MDNA55 is the Company's lead product. MDNA55 is being studied in clinical trials for treatment of CNS cancers. The Company's MDNA56 and MDNA57 are its IL-4 carrying a human cell killing payload. MDNA56 is being developed for the treatment of hematopoietic cancers expressing the Type 1 IL-4R, whereas MDNA57 is intended to selectively target solid tumors and non-malignant cells of the tumor micro-environment expressing the Type 2 IL-4R.
| Last Annual | March 31st, 2020 |
| Last Interim | June 30th, 2020 |
| Incorporated | February 2, 2015 |
| Public Since | July 13, 2015 |
| No. of Shareholders: | n/a |
| No. of Employees: | 7 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | Toronto Stock Exchange |
| Shares in Issue | 48,797,983 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 2 Bloor St W 7th Floor, TORONTO, M4W 3E2, Canada |
| Web | https://www.medicenna.com |
| Phone | +1 416 6485555 |
| Auditors | Davidson & Co LLP |
As of 10/08/20, shares in Medicenna Therapeutics are trading at C$5.78, giving the company a market capitalisation of £152.8m. This share price information is delayed by 15 minutes.
Shares in Medicenna Therapeutics are currently trading at C$5.78 and the price has moved by 0.321k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Medicenna Therapeutics price has moved by 0.315k% over the past year.
Of the analysts with advisory recommendations for Medicenna Therapeutics, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Medicenna Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Medicenna Therapeutics is scheduled to issue upcoming financial results on the following dates:
Medicenna Therapeutics does not currently pay a dividend.
Medicenna Therapeutics does not currently pay a dividend.
Medicenna Therapeutics does not currently pay a dividend.
To buy shares in Medicenna Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Medicenna Therapeutics are currently trading at C$5.78, giving the company a market capitalisation of £152.8m.
Here are the trading details for Medicenna Therapeutics:
Based on an overall assessment of its quality, value and momentum, Medicenna Therapeutics is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Medicenna Therapeutics are currently priced at C$5.78. At that level they are trading at 0.108% discount to the analyst consensus target price of 0.00.
Analysts covering Medicenna Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -0.328 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medicenna Therapeutics. Over the past six months, the relative strength of its shares against the market has been 82.34%. At the current price of C$5.78, shares in Medicenna Therapeutics are trading at 52.32% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Medicenna Therapeutics.
We were unable to find the directors for Medicenna Therapeutics.
Here are the top five shareholders of Medicenna Therapeutics based on the size of their shareholding:
